Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 4/20 | 0.63 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.49 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | MMP3 | P08254 | 1/20 | 0.46 |
| ▸ | FCER2 | P06734 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | GNPAT | O15228 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7062118 | 1.00 | PTPN1 (0.63) | PTPN1PTPN2MMP1MMP3FCER2 | |
| SCHEMBL7062116 | 1.00 | PTPN1 (0.63) | PTPN1PTPN2MMP1MMP3FCER2 | |
| SCHEMBL7570995 | 0.81 | PTPN1 (0.71) | PTPN1PTPN2MMP1FCER2CTSL | |
| SCHEMBL7571001 | 0.81 | PTPN1 (0.71) | PTPN1PTPN2MMP1FCER2CTSL | |
| SCHEMBL7576946 | 0.81 | PTPN1 (0.71) | PTPN1PTPN2MMP1FCER2CTSL | |
| SCHEMBL7568932 | 0.78 | PTPN1 (1.00) | PTPN1PTPN2 | |
| SCHEMBL7065596 | 0.78 | PTPN1 (1.00) | PTPN1PTPN2 | |
| SCHEMBL7065601 | 0.78 | PTPN1 (1.00) | PTPN1PTPN2 | |
| SCHEMBL6493488 | 0.76 | ITGB3 (0.49) | PTPN1PTPN2LMNAGNPAT | |
| SCHEMBL6493485 | 0.76 | ITGB3 (0.49) | PTPN1PTPN2LMNAGNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313696-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | disclosed |
| WO-2002018323-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | PPM1A, PTPRO, PTP4A1 | PTPN1 10/4885PTPN2 29/4885MMP1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.